Teva and Lonza are re-evaluating the potential of their joint venture to develop, manufacture and market biosimilars. The companies are exploring the best routes to realizing the benefits of biosimilars for certain biologics. With regulatory uncertainty in the biosimilars arena, both companies are taking a measured approach to fully evaluate regulatory and commercial circumstances before agreeing on further long-term investments.